Clinical trial
Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected…
NCT00395252 · Carmen Schade-Brittinger, Other · Completed
Key facts
| NCT number | NCT00395252 |
|---|---|
| Title | Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer |
| Official title | Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer |
| Acronym | ATIP |
| Lead sponsor | Carmen Schade-Brittinger, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Cetuximab (Erbitux®) and Gemcitabine |
| Enrollment | 76 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | Nov 2, 2006 |
| Last update posted | Oct 2, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: